Literature DB >> 7588263

Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis.

R Day1, W Dong, R Panetta, J Kraicer, M T Greenwood, Y C Patel.   

Abstract

To characterize cell specific expression of sstr subtypes in the pituitary we have analyzed mRNA for sstr1-5 in rat pituitary somatotrophs by reverse transcriptase polymerase chain reaction and determined the pattern and level of expression of mRNA for sstr subtypes 2 and 5 in individual pituitary cell subpopulations by double label in situ hybridization. Purified somatotrophs expressed mRNA for all 5 sstrs. In situ hybridization analysis revealed sstr5 mRNA in 70% of somatotrophs, 57% of thyrotrophs, 38% of corticotrophs, 33% of lactotrophs, and 21% of gonadotrophs. mRNA for sstr2 occurred in 40% of somatotrophs, 36% of thyrotrophs, 26% of lactotrophs, 3% of corticotrophs, and 8% of gonadotrophs. Not only were more cells positive for sstr5 mRNA but the average number of autoradiographic grains/cell was also higher for sstr5 than sstr2. These results show expression of multiple sstr genes in individual pituitary cells. mRNA for sstr2 and 5 occur in each of the 5 major pituitary cell subsets, sstr5 mRNA being more widely and more abundantly expressed than sstr2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588263     DOI: 10.1210/endo.136.11.7588263

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 2.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 4.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 5.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

6.  Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

Authors:  Masaaki Yamamoto; Anat Ben-Shlomo; Hiraku Kameda; Hidenori Fukuoka; Nan Deng; Yan Ding; Shlomo Melmed
Journal:  JCI Insight       Date:  2018-10-04

Review 7.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 8.  Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.

Authors:  Ilan Shimon
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 9.  Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2012-12-31       Impact factor: 3.750

10.  Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma.

Authors:  Wael Hassaneen; Daniel P Cahill; Gregory N Fuller; Nicholas B Levine
Journal:  J Neurooncol       Date:  2009-11-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.